Development of small-molecules targeting CD93-signaling for the treatment of leukemia
At a glance
- Project leader : Prof. Dr. Rainer Riedl, Dr. Carsten Riether
- Project team : Dr. Michael Brand
- Project budget : CHF 483'000
- Project status : completed
- Funding partner : Innosuisse (Innovationsprojekt / Projekt Nr. 47219.1 IP-LS)
- Project partner : Inselspital Bern
- Contact person : Rainer Riedl
Description
The aim of the current InnoSuisse application is to optimize small molecules, which were identified in a drug library screen to block CD93-signaling in LSCs and showed a positive clinical response, in order to develop lead candidates with a novel chemical scaffold and own IP to treat leukemia.